AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

Citation

• Powderly, J. D., de Souza, P. L., Gutierrez, R., Horvath, L., Seitz, L., Ashok, D., . . . Chaudhry, A. (2019). AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.. Journal of Clinical Oncology, 37(15_suppl), 2604. doi:10.1200/jco.2019.37.15_suppl.2604

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.2604

Web Of Science Accession Number

Start Page

• 2604

End Page

• 2604

Volume

• 37

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2019

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Powderly, J. D., de Souza, P. L., Gutierrez, R., Horvath, L., Seitz, L., Ashok, D., . . . Chaudhry, A. (2019). AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.. Journal of Clinical Oncology, 37(15_suppl), 2604. doi:10.1200/jco.2019.37.15_suppl.2604

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.2604

Web Of Science Accession Number

Start Page

• 2604

End Page

• 2604

Volume

• 37

Issue

• 15_suppl

Place Of Publication